The EDV is a platform technology and has the potential to address multiple solid tumor indications. Currently EnGeneIC is conducting clinical studies in the following areas.
- Cerebral EDV for Recurrent glioma. Phase I ongoing at Johns Hopkins Hospital, Baltimore, USA in recurrent glioma has shown safety and promising increased overall survival using EGFR targeted EDVs carrying doxorubicin. Subsequently, an IND has been accepted by the FDA to initiate a Phase I/IIa trial at major hospitals in the US. For more information click here
- Tailored EDV trial. This “intention to treat” trial is aimed at better informing us as to which tumor indications will respond best to EDV-based therapeutics. Patients who have run out of curative treatment options can be treated with EDVs carrying different payloads. In this trial, EDVs carrying a super toxic drug, plus, an EDV carrying a nucleic acid.
- Kid EDV trial. This Phase I trial in children with recurrent or refractory neurological or solid tumors will test EGFR-targeted EDVs carrying mitoxantrone. Phase I ongoing in Sydney, Australia, for more information click here
- Mesomir Advanced mesothelioma (malignant pleural mesothelioma, MPM). Phase I study has recently been completed and published in Lancet Oncology.
Proprietary drugs. In early stage trials most patients enrolled have had multiple lines of chemotherapy and are generally chemo-resistant. We are developing our own drugs which are highly toxic and cannot be given systemically but are safe when delivered via the EDV. In laboratory tests and in animal models, these drugs prove to be up to 1000x more potent than conventional chemotherapy and are able to totally overcome drug resistance. One of these drugs is undergoing toxicology screens and if safe will be committed to the tailored EDV trial.
Next generation EDV-therapeutics. We and our collaborators are working on a number of product candidates for intractable tumors such as pancreatic cancer, as well as new antibodies to target tumors other than EGFR. We are also investigating ways in which to enhance the EDV-stimulated adaptive immune response in the majority of patients.